福建地区畲族的骨密度与骨生化指标以及睾酮雌二醇之间的关系

目的探讨福建地区畲族健康人群骨密度与骨生化指标以及睾酮雌二醇之间的关系,并与汉族人群比较,为本地区骨质疏松防治提供依据。方法选择本地区畲族聚集地20岁以上健康成年人,其中畲族1371人,汉族1432人,应用美国Osdeometer Medi Tech公司生产的DTX-200骨密度吸收仪检测骨密度,以及用罗氏公司的骨生化指标仪器及试剂盒,测量骨密度以及25羟维生素D3(25(OH)D_3)、骨钙素(BGP)、雌二醇(E_2)、睾酮(T)、甲状旁腺激素(PTH)、1型前胶原氨基末端肽(P1NP)、碱性磷酸酶(ALP)。把上述检测的数据结果输入电脑,应用SPSS17.0软件包进行数据分析。结果不管畲族和汉族的骨密度均随着年龄的增大而下降,同年龄组男性均高于女性。畲族女性除在40~49岁年龄组稍高于汉族外,其他年龄组汉族女性均高于畲族。但汉族与畲族间都没有显著性差异(P0.05)。畲族男PO女性的骨密度峰值在40~49岁年龄组,汉族的男女性的峰值在30~39岁年龄组。汉族的25(OH)D_3明显高于畲族,尤其女性在40~59岁年龄组、男性在50~69岁年龄组为正相关(P0.05)。在40~69岁中畲族男性的BGP高于汉族男性(P0.05).汉族男的E2指标均高于畲族男,且40~59年龄组尤为明显(P0.05)。P1NP在汉族男女性高于畲族男女性,其中50~59岁,70岁~79岁,和80以上3组的汉族男和畲族男P1NP指标差异显著(P0.05),50岁以上4组汉族女P1NP指标均比畲族女高,差异显著(P0.05)。经皮尔森相关分析,骨密度与E2、25(OH)D_3、T成正相关,而与PTH、BGP、P1NP成负相关。结论本研究25(OH)D3、BGP、P1NP、E2测定可以作为汉族、畲族健康人群早期检测指标,畲族的25(OH)D_3水平普遍偏低,可能与他们的生活方式或者维生素D基因有关,值得进一步研究。骨密度与25(OH)D_3、E_2、T有明显正相关,而与PTH、PINP、BCG呈负相关,与ALP无明显相关。     

长春市8955例汉族人群骨密度测量结果分析

目的 通过8955例长春市汉族人群骨密度测量,提供本地区骨密度正常参考值及峰值骨量,分析骨质疏松发生的人群规律.方法 采用美国Osteometer Medi Tech公司生产的DTX-200 型骨密度仪,检测受试者非受力侧前臂尺桡骨中远端三分之一处骨密度(BMD).将8955例检测结果按不同性别每10岁分为一年龄组统计分析骨密度均值,T评分及骨量丢失百分率.结果 长春市区男女BMD峰值分别为0.6244±0.098、0.5050±0.064,其BMD峰值出现在30岁年龄段,50岁以后开始缓慢下降.50～59岁男性OP发生率为6.95%,女性为8.52%;60～69岁男性OP发生率为19.66%,女性为35.44%;70～79岁男性OP发生率为38.39%,女性为60.64%;80岁以上男性OP发生率为58.17%,女性为72.73%.结论 不同年龄组及同年龄组两性间比较BMD测定值差异显著(P＜0.01),50岁以后各年龄段女性OP发生率明显高于男性(P＜0.01).不同地域、不同民族、不同仪器检测的BMD数据存在差异.     

2510名浙江居民指骨骨密度检测结果分析

目的 了解受检人群的指骨骨密度(BMD)情况,为骨质疏松的防治计划奠定基础.方法 通过健康快车活动在2011年6月至2011年7月在浙江省对2510名志愿者(男性734人,女性1776人,年龄范围20～85岁,平均为55.62±14.13岁)的指骨骨密度数据进行分析.结果 受检人群骨量峰值出现在35～40年龄组,男性＞65岁和女性＞50岁BMD低于35 ～ 40年龄组(P＜0.05);三指骨骨密度有差别,MP3＞ MP2＞ MP4(F =493.647,P=0.000);男性BMD高于女性(F=788.027,P=0.000).男性20～40年龄组骨质正常占86.32％,50～60年龄组骨质正常为80.86％,而到70～85年龄组骨质正常只有56.02％;女性20～40年龄组骨质正常占88.51％,50～60年龄组骨质正常为52.29％,而到70 ～ 85年龄组骨质正常只有13.27％.结论 浙江省受检人群的指骨BMD有明显的性别和年龄差异,其中女性＞50岁指骨BMD呈直线下降趋势,应加强对这一人群骨质疏松的预防和治疗;指骨骨密度仪简易、快速、便携、有效,作为普查工具具有一定的可行性.     

莆田地区畲族的骨密度与骨生化指标以及睾酮雌二醇之间的关系

目的 探讨莆田地区畲族健康人群骨密度与骨生化指标、睾酮以及雌二醇之间的关系,并与汉族人群比较,为本地区骨质疏松防治提供依据。方法 选择本地区畲族聚集地40岁以上健康成年人,其中畲族532人,汉族563人,应用美国Osteometer Medi Tech公司生产的DTX-200骨密度吸收仪检测骨密度,以及用罗氏公司的骨生化指标仪器及试剂盒,测量骨密度以及25羟维生素D（25（OH）D3）、骨钙素（BGP）、雌二醇（E2）、睾酮（T）、甲状旁腺激素（PTH）、1型前胶原氨基末端肽（P1NP）、碱性磷酸酶（ALP）。把上述检测的数据结果输入电脑,应用SPSS17.0软件包进行数据分析。结果 不管畲族和汉族的骨密度均随着年龄的增大而下降,同年龄段男性均高于女性。畲族女性除在40～49岁年龄段稍高于汉族外,其他年龄组汉族女性均高于畲族。而畲族男性在60～69岁年龄段稍高于汉族男性,其他年龄组汉族男性均高于畲族,但汉族与畲族间都没有显著性差异（P>0.05）。汉族的25(OH)D3明显高于畲族,尤其女性在40～60岁年龄段、男性在50～69岁年龄段为正相关（P<0.05）;汉族的BGP高于畲族(P<0.05),汉族男的E2指标均高于畲族男,且40～59年龄段尤为明显（P<0.05）。P1NP在汉族男女性高于畲族男女性（P<0.05）。经皮尔森相关分析,骨密度与E2、25OHD3、T成正相关,而与PTH、BGP、ALP成负相关,与ALP无相关。结论 本研究25（OH）D3、BGP、P1NP、E2测定可以作为汉族、畲族健康人群早期检测指标,畲族的25（OH）D3水平普遍偏低,可能与他们的生活方式或者维生素D基因有关,值得进一步研究。骨密度与25（OH）D3、E2、T有明显正相关,而与PTH、PINP、BCG负相关,与ALP无明显相关。     

哈尔滨地区379例女性跟骨超声骨量的研究

目的 调查哈尔滨地区部分成年女性跟骨骨密度,为该地区正常骨密度参考标准的建立及数据积累提供资料.方法 应用法国Osteospace MEDI LINK骨密度仪,利用定量超声法测量379例人群跟骨超声骨量.结果 统计出不同年龄组超声速度(SOS)、骨硬度指数(STI)、低骨量(LBM)及骨质疏松(OP)比例.结论 哈尔滨地区成年女性SOS峰值在35～岁年龄组,至50～岁年龄组明显下降;STI峰值在35～岁年龄组,以后随着年龄的增长而降低,至55～岁年龄组明显下降;50～岁年龄组低骨量和骨质疏松比例明显增加,且随年龄增长比例呈现继续增长趋势.     

京城区居民骨密度随年龄变化的特点--3285例骨密度测定结果分析

目的 了解北京城区居民骨密度(BMD)的变化规律和骨质疏松症(OP)的患病率.方法 应用法国MEDILINK公司牛产的OSTEOCORE1型双能X线骨密度仪对北京市城区3285名20～89岁人群进行股骨近端及腰L2-L4椎的BMD测定.结果 北京市城区男、女性人群的股骨近端及腰椎的BMD峰值均出现在20～29岁年龄组,峰值后随着年龄的增长骨密度BMD降低,女性在50～59岁BMD下降明显加速,男性没有出现下降加速现象.北京市城区中国人40岁以后OP患病率男性23.19%,女性OP患病率28.7%.结论 通过对北京市城区中国人群的BMD变化规律及患病率研究,为北京市城区中国人群的骨质疏松症预防、诊断及治疗提供客观有效的依据.     

双能X线骨密度仪测定成都市城区771例健康人骨密度结果分析

目的观察成都市城区健康人群骨密度变化规律,建立该型骨密度仪成都地区骨密度正常值,为骨质疏松诊断、防治提供参考依据。方法①采用EXPERT-XL双能X线骨密度仪(美国 LUNAR公司生产)测定成都市城区健康体检者771例,其中男性300例,女性471例,测量部位包括腰椎1～4和髋部;②按年龄、性别分别输入数据,以10岁为一年龄组,分别计算各组骨密度值,结果以x-±s表示。结果男性腰椎及股骨近端骨密度峰值出现在30～39岁,女性腰椎及股骨近端骨密度峰值出现在20～29岁,随着年龄增加,骨密度逐渐降低,男性在70岁后腰椎骨密度有反弹,而女性在50～59岁间骨密度下降迅速。结论本组健康人群骨密度数据将为成都地区骨质疏松诊断、防治提供参考依据;分析男性腰椎骨密度时应结合股骨近端骨密度;女性50岁后应注意预防、治疗骨质疏松,男性骨质疏松不容忽视。     

大庆地区1096例汉族人群骨密度调查及骨质疏松发生率分析

目的 调查大庆市1096例健康汉族人群骨密度,了解该地区健康人群骨量峰值、骨密度变化的规律及骨质疏松发生率。方法 采用美国GE公司生产的Luner Prodigy Advance型骨密度仪,检测受试者腰椎和股骨颈骨密度（BMD）。将1096例检测结果按不同性别每5岁为1年龄组,应用SPSS19.0软件统计分析骨密度测量指标及骨质疏松（OP）发生率。结果 大庆市汉族男、女性人群腰椎骨密度峰值分别为1.197±0.203、1.192±0.145,股骨颈骨密度峰值分别为0.977±0.157、0.918±0.128。其峰值骨量年龄男性为45～49岁,50岁以后开始缓慢下降。其峰值骨量年龄女性为40～49岁,50岁以后开始缓慢下降。50～54岁年龄段男性骨质疏松症发生率为5.56%,女性为5.67%;55～59岁年龄段男性骨质疏松症发生率为7.32%,女性为11.51%;60～64岁年龄段男性骨质疏松症发生率为15.15%,女性为28.28%;65～69岁年龄段男性骨质疏松发生率为26.67%,女性为29.41%;70～74岁年龄段男性骨质疏松发生率为25.00%,女性为44.44%;75～79岁年龄段男性骨质疏松发生率为36.36%,女性为77.78%;80岁以上男性骨质疏松发生率为66.67%,女性为83.33%。结论 大庆市汉族人群不同年龄及同年龄组两性之间比较骨密度测定值差异显著（P<0.01）。55岁以后各年龄段女性骨质疏松发生率明显高于男性（P<0.01）。本研究报告的骨密度峰值大于沈阳地区,与合肥地区相近,略低于贵阳地区。OP发生率与合肥地区比较相近,略低于沈阳地区。     

南京地区不同人群骨量变化及临床意义

目的分析南京地区人群的峰值骨量及骨密度变化的规律。方法 10599例受试者被分为两组,A组为9795例的男性和女性,B组为804例有脆性骨折的女性,所有入选人群均行双能X线骨密度测量仪测量腰椎和髋部的骨密度(BMD)。将A组按5岁为一年龄组,分为14组,B组按10岁为一年龄组,分为4组。结果男性腰椎骨峰值年龄出现在30～34岁,股骨颈,Ward's三角及大转子的骨峰值年龄在25～29岁;女性腰椎骨峰值出现在35～39岁,股骨颈,Ward's三角及大转子骨峰值年龄在30～34岁。脆性骨折女性各部位的BMD均丢失明显。结论 南京地区男性35岁后和女性40岁后骨量将逐渐下降,脆性骨折患者骨密度丢失显著。50岁以上女性和65岁以上男性应重视骨密度的定期检查。     

北京地区健康绝经期前女性骨转换标志物Ｐ１ＮＰ 和β⁃ＣＴＸ 的参考区间分析

目的　分析北京地区健康绝经期前女性不同年龄阶段血清Ｉ 型原胶原氨基端肽（ｐｒｏｃｏｌｌａｇｅｎ ｔｙｐｅ １ Ｎ?ｔｅｒｍｉｎａｌ ｐｒｏｐｅｐｔｉｄｅ, Ｐ１ＮＰ）和Ｉ 型胶原羧基端肽交联（β ｃｒｏｓｓ?ｌｉｎｋｅｄ Ｃ?ｔｅｌｏｐｅｐｔｉｄｅ ｏｆ ｔｙｐｅ １ ｃｏｌｌａｇｅｎ, β?ＣＴＸ）水平的分布趋势差异并初 步建立两者的参考区间。方法　以北京地区健康绝经期前女性作为研究对象,应用罗氏电化学发光免疫分析技术,对符合入 组标准的２７２ 名３０ ～５４ 岁女性血清Ｐ１ＮＰ 和β?ＣＴＸ 水平进行检测。以５ 岁为一年龄段进行分组：３０ ～３４ 岁,３５ ～３９ 岁,４０ ～ ４４ 岁,４５ ～４９ 岁,５０ ～５４ 岁;运用局部加权回归散点平滑法和Ｋｏｌｍｏｇｏｒｏｖ?Ｓｍｉｒｎｏｖ Ｚ 检验比较不同年龄段两者的组间分布趋势 差异,确定参考人群的特异年龄段,并应用非参数方法建立参考区间。结果　２７２ 名入组受试者的平均年龄为（３９?? ５１ ±５?? ８５） 岁,总体Ｐ１ＮＰ 与β?ＣＴＸ 水平呈非正态分布。３５ ～３９ 岁与４０ ～４４ 岁的血清Ｐ１ＮＰ 与β?ＣＴＸ 水平分布趋势比较差异无统计学 意义（Ｐ ＞０?? ０５）;进一步将３０ ～３４ 岁及４５ ～４９ 岁水平分别与３５ ～４４ 岁水平的分布趋势比较,差异有统计学意义（Ｐ ＜０?? ０５）。 因此将３５ ～４４ 岁年龄段的健康绝经期前女性作为参考人群,由此所建立的血清Ｐ１ＮＰ 参考区间为： １７?? ９５ ～ ６５?? ６０ ｎｇ／ ｍＬ,血 清β?ＣＴＸ 参考区间为０?? １０ ～ ０?? ４９ ｎｇ／ ｍＬ。结论　北京地区３５ ～ ４４ 岁健康绝经期前女性血清骨转换标志物Ｐ１ＮＰ 和β?ＣＴＸ 水平分布趋势相对平稳,受变异因素影响最小,两者在此年龄段人群的测定结果适宜作为建立参考区间的参考值。     

Localization of carboxy-terminal type II procollagen peptide (pCOL-II-C) in diseased cartilage

A well characterized rabbit polyclonal antibody against human carboxy-terminal type II procollagen peptide (pCOL-II-C) was used to study the immunolocalization of pCOL-II-C in articular cartilage obtained from patients with osteoarthritis (OA), rheumatoid arthritis (RA), and control non-diseased joints. In moderately degenerative OA cartilage, immunoreactive chondrocytes were observed in all layers, particularly along the margins of fibrillation and fissures, in chondrocyte clusters and in osteochondrophytes. The grade of immunostaining in OA correlated directly with Mankin's histological-histochemical scores of 0–7, but there was an inverse correlation between grade of immunostaining and Mankin's scores of 8–14. The grade of immunostaining was significantly higher in OA than in RA and normal control cartilage. Since type II collagen is a unique component of articular cartilage, localization of pCOL-II-C could reflect the increased synthesis of type II collagen by chondrocytes in diseased cartilage. This study was presented at the 8th Annual Meeting for Orthopaedic Research of the Japanese Orthopaedic Association in October 1993, at Matsumoto and at the 7th Annual Meeting of Japanese Society of Cartilage Metabolism in March 1994, at Hiroshima     

Laminin and aminoterminal propeptide of type III procollagen in seminal plasma from fertile and vasectomized men

Summary. The components of the extracellular matrix, laminin and aminoterminal propeptide of type III procollagen (PIIINP) were determined in seminal plasma of 50 patients with vasectomy and of 50 age-matched fertile patients. The concentration of laminin was highly significantly ( P < 0.001) elevated in the fertile group as compared to the vasectomy group, whereas the concentrations of PIIINP were not significantly different between these two groups. Only weak correlations were observed between the concentrations of laminin and PIIINP. It is suggested that part of the laminin found in seminal plasma is derived from the ductus deferens, while the source of PIIINP is probably located at an upper part of the urogenital tract.     

The concentration pattern of laminin, hyaluronan, and aminoterminal propeptide of type III procollagen in seminal fluid

The extracellular matrix components laminin, N-terminal propeptide of type III procollagen (PIIINP) and hyaluronan (HA) were determined in seminal fluids of 119 patients submitted for diagnosis of infertility. The concentrations of laminin and HA, but not those of PIIINP, were elevated in seminal fluid in comparison to their ranges of concentration in normal sera. Only weak correlations were observed between the concentrations of the three matrix components. The concentration of HA was negatively correlated with sperm count and ejaculate volume. Laminin was positively correlated with sperm count, the age of patients, and highly significantly with the concentrations of acrosin. A highly significant positive correlation was also found between PIIINP and fructose. By analysis of variance it could be shown that patients with azoospermia and oligozoospermia have significantly higher levels of HA than those with normospermia. Patients with terato- and asthenozoospermia showed no characteristic pattern of the matrix components.     

Biochemical markers of bone formation in the study of postmenopausal osteoporosis

A comparative study was performed on the sensitivity of the determination of the available biochemical markers of bone formation — total and bone alkaline phosphatase (TAP and bAP, respectively), osteocalcin (BGP), procollagen I aminoterminal propeptide (PINP) and procollagen I carboxyterminal propeptide (PICP) — in the study of postmenopausal osteoporosis. The comparison between PINP and PICP, due to the recent development of the amino-terminal assay, is of special interest. The study included 26 untreated osteoporotic postmenopausal women, age 59±6 years (range 46–69 years) and 17 healthy control postmenopausal women, age 56±7 years (range 48–70 years). We found a significant increase in the levels of bAP (p=0.0021), BGP (p=0.041), PINP (p=0.0001) and PICP (p=0.0073), but not in the levels of TAP (p=0.3389), in osteoporotic patients with respect to the control group. Serum PINP and bAP showed the highest diagnostic accuracy among the markers of bone formation studied, as can be deduced from the receiver operating characteristics (ROC) curves. In spite of their similar origin (amino-terminal and carboxy-terminal release from a procollagen molecule), the results obtained by measuring levels of PINP are significantly better than those found with PICP.     

2型糖尿病合并微血管病变与骨转换标志物的相关性

目的探讨2型糖尿病合并微量白蛋白尿、视网膜病变患者骨转换标志物的变化。方法选取301名成人2型糖尿病患者,将合并微量白蛋白尿和(或)视网膜病变患者作为试验组,无微量白蛋白尿和视网膜病变患者作为对照组,运用统计学分析比较两组间I型原胶原N-端前肽(procollagentype I N-terminal propeptide,PINP)、β-异构C-端肽(beta-isomerized Ctelopeptide,β-CTX)以及相关资料的差异,并对两组骨转换标志物进行相关性分析。结果两组间血清PINP的比较,差异无统计学意义(P0.05);试验组β-CTX明显高于对照组(P=0.001);相关分析显示β-CTX与BUN(γ=-0.431,P=0.013)、Cr(γ=-0.602,P=0.013)、UA(γ=-0.538,P=0.012)、25(OH)D3(γ=-0.703,P=0.036)呈负相关,与HbA1c(γ=0.235,P=0.030)、PTH(γ=0.652,P=0.000)呈正相关。结论 2型糖尿病合并微量白蛋白尿和视网膜病变时,β-CTX明显增高,认为β-CTX可能成为监测2型糖尿病微血管病变患者骨代谢变化的特异性指标。     

The effect of a short course of calcium and vitamin d on bone turnover in older women

Calcium and vitamin D (1200 mg/day + 800 IU) has been shown to reduce hip fracture incidence in older women living in long-term care facilities who had borderline low vitamin D levels. We examined the effect of a short course of calcium and vitamin D on biochemical markers of bone turnover in older community-living women. Twelve community-living women (mean age 75 years) in good general health, without diseases or on medications known to affect bone, were entered into the study. All women were treated with calcium citrate (1500 mg/day of elemental calcium) and vitamin D₃ (1000 IU/day) (Ca + D) for 6 weeks. Biochemical markers of bone turnover were measured in serum and urine collected at baseline (two samples), 5 and 6 weeks on Ca + D, and 5 and 6 weeks after termination of Ca + D. Markers of bone formation were osteocalcin, bone alkaline phosphatase and type I procollagen peptide. Markers of bone resorption were urinary hydroxyproline, free pyridinoline and deoxypyridinoline crosslinks, and N-telopeptides of type I collagen. Parathyroid hormone (PTH) and 25-hydroxyvitamin D were also measured at baseline, 6 weeks on treatment and 6 weeks after termination of treatment. All markers of bone resorption decreased on Ca + D and returned to baseline after termination of Ca + D (p<0.05). Markers of bone formation did not change with Ca + D treatment. PTH decreased on Ca + D and returned to baseline after treatment, and 25-hydroxyvitamin D increased with treatment and remained elevated 6 weeks after the end of treatment. We conclude that Ca + D reduces bone resorption in older women, possibly by suppressing PTH levels.     

Vertebral Fracture Risk Is Reduced in Women Who Lose Femoral Neck BMD With Teriparatide Treatment

Response to osteoporosis therapy is often assessed by serial BMD testing. Patients who lose BMD without secondary causes of bone loss may be considered to be “nonresponders” to treatment. We examined vertebral fracture (VF) risk, change in lumbar spine (LS) BMD, and change in amino‐terminal extension peptide of procollagen type I (PINP) in postmenopausal women whose femoral neck (FN) BMD decreased, increased, or was unchanged after receiving teriparatide (TPTD) or placebo (PL) in the Fracture Prevention Trial. FN and LS BMD were measured at baseline and 12 mo. VFs were assessed by lateral spine radiographs at baseline and study endpoint. A BMD change from baseline of >4% was considered to be clinically significant. Decreases of >4% FN BMD were less common in women receiving TPTD (10%) versus PL (16%, p < 0.05), yet women on TPTD who lost FN BMD still had significant reductions in VF risk compared with PL (RR = 0.11; 95% CI = 0.03–0.45). VF risk reduction with TPTD compared with PL was similar across categories of FN BMD change from baseline at 12 mo (loss >4%, loss 0–4%, gain 0–4%, or gain >4%; interaction p = 0.40). Irrespective of FN BMD loss or gain, TPTD‐treated women had statistically significant increases in LS BMD and PINP compared with PL. In both groups, losses or gains in FN BMD at 12 mo corresponded to losses or gains in BMC rather than changes in bone area. In conclusion, loss of FN BMD at 12 mo in postmenopausal women with osteoporosis treated with TPTD is nevertheless consistent with a good treatment response in terms of VF risk reduction.     

Upregulation of tissue inhibitor of metalloproteases-1 (TIMP-1) and procollagen-N-peptidase in hypertension-induced renal damage.

BACKGROUND: Hypertensive renal damage starts in the juxtamedullary cortex (JMC) and gradually extends towards the outer cortex (OC). The intention of the study was to examine if the increase of fibrous tissue in the JMC of the spontaneously hypertensive rat (SHR) is dependent on an increase of collagen synthesis or a decreased collagen breakdown compared to the normotensive control (WKY). METHODS AND RESULTS: The renal damage was evaluated by light microscopy, and the amount of fibrosis was quantified using Sirius red staining. Real-time RT-PCR was used to quantify mRNA for: collagen-type-1-alpha-1 (col1a1), procollagen-n- and -c-proteinase, matrix metalloproteases, MMP-2 and MMP-9, tissue inhibitor of metalloproteases, TIMP-1 and TIMP-2. Western blot was used to quantify the proteins of MMP-2, MMP-9, TIMP-1 and TIMP-2. The relative activities of MMP-2 and MMP-9 were assayed by zymography. The JMC in SHR had an increased amount of collagen as measured by Sirius red, and a 15-fold increase in the mRNA for col1a1. The gene expression of procollagen-c-proteinase was unchanged while procollagen-n-proteinase was increased in SHR and had the highest expression in the JMC. The mRNA for MMP-2 and MMP-9 showed increased expression in SHR, but not specifically in the JMC. Protein analysis showed increased expression for MMP-2 in SHR and in the JMC. MMP-9 protein was lower in SHR. TIMP-1 was increased in SHR at both mRNA and protein level and more so in the JMC. The mRNA and protein analysis of TIMP-2 showed small differences between SHR and WKY. CONCLUSION: An imbalance of collagen metabolism featuring increased synthesis and inhibition of breakdown favours renal interstitial fibrosis in SHR.     

Stimulative Effect of Transforming Growth Factor-β on Collagen Synthesis by Human Prostatic Stromal Cells In Vitro

Background :
Expression of transforming growth factor-β (TGF-β) in the prostate has been reported. The purpose of this study was to evaluate the effect of TGF-β on collagen synthesis by stromal cells isolated from a patient with benign prostatic hyperplasia (BPH).
Methods :
Human prostatic stromal cells (HPSC) derived from BPH tissue were cultured in serum-free medium. After incubation with TGF-β1, the concentration of procollagen type I C-peptide (PIP) in the HPSC-conditioned medium was measured by enzyme immunoassay while the concentration of procollagen type III N-peptide (PIIIP) was measured by radioimmunoassay. Per-cell production of each type of collagen was calculated by multiplying the measured concentration by the volume of medium and dividing by the number of harvested cells.
Results :
One ng/mL of TGF-β1 significantly ( P< 0.05) increased collagen production by HPSC, to 220% and 120% of control for types I and III, respectively. Increasing the amount of TGF-β1 to 10 ng/mL had no further effect. TGF-β1 did not significantly affect HPSC number at concentrations of either 1 or 10 ng/mL. There was a strong correlation between PIP and PIIIP production (r= 0.929, P< 0.001).
Conclusion :
These findings suggest that TGF-β stimulates accumulation of extracellular matrix in stromal BPH tissue without affecting proliferation of stromal cells.